Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2025-12-25 @ 2:43 AM
NCT ID:
NCT00651833
Eligibility Criteria:
Inclusion Criteria:
* 1\. Has given written informed consent. 2. Patients with histologically and/or cytologically proven unresectable NSCLC stage IIIB with pleural effusion or pericardial effusion, or stage IV (mixed forms with small cell lung cancer are excluded).
3\. Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, ie, has at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm using spiral Computed Tomography (CT) scan.
4\. Is able to take medications orally. 5. Is ≥ 18 years of age. 6. Has an ECOG performance status 0 or 1. 7. Has adequate organ function as defined by the following criteria:
1. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN; if liver function abnormalities are due to underlying liver metastasis AST (SGOT) and ALT (SGPT) ≤ 5 x ULN.
2. Total serum bilirubin of ≤ 1.5 x ULN.
3. Absolute granulocyte count of ≥ 1,500/mm3.
4. Platelet count ≥ 100,000/mm3.
5. Hemoglobin of ≥ 9.0 g/dL.
6. Calculated creatinine clearance (CrCl) ≥ 60 mL/minute (Cockcroft-Gault formula).
8\. Is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
* 1\. Has had treatment with any of the following within the specified time frame prior to study drug administration:
1. Any prior cytotoxic chemotherapy except for adjuvant or neo-adjuvant therapy for NSCLC beyond 12 months.
2. Any radiation therapy to a target lesion unless there was evidence of PD after radiotherapy (and this target lesion must not be the only site of measurable disease).
3. Radiotherapy within the prior 2 weeks.
4. Adjuvant or neo-adjuvant therapy within the past 12 months.
5. Prior cisplatin as neo-adjuvant and/or adjuvant chemotherapy with cumulative dose \> 300 mg/m2.
6. Any investigational agent, either concurrently or within the past 30 days.
7. Current enrollment in another clinical study with an investigational agent. Patients participating in surveys or observational studies are eligible to participate in this study.
2\. Has a serious illness or medical condition(s) including, but not limited to, the following:
<!-- -->
1. Other active malignancies.
2. Symptomatic brain metastasis not controlled by corticosteroids.
3. Leptomeningeal metastasis.
4. Known neuropathy Grade 2 or higher.
5. Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure New York Heart Association (NYHA) class III or IV.
6. Chronic nausea, vomiting, and/or diarrhea.
7. Psychiatric disorder that may interfere with consent and/or protocol compliance.
8. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
3\. Is receiving concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:
<!-- -->
1. Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1 activity).
2. Allopurinol (may diminish S-1 activity).
3. Phenytoin (S-1 may enhance phenytoin activity).
4. Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity).4. Is receiving concomitant treatment with drugs interacting with cisplatin. The following drugs are prohibited because there may be an interaction with cisplatin:
<!-- -->
1. Phenytoin (cisplatin may diminish phenytoin activity).
2. Aminoglycosides (should be avoided within 8 days after cisplatin administration).
5\. Is a pregnant or lactating female. 6. Has known hypersensitivity to cisplatin. 7. With reproductive potential and refuses to use an adequate means of contraception (including male patients).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00651833
Study Brief:
Protocol Section:
NCT00651833